Hydroxychloroquine Therapy in Rheumatoid Arthritis

Primary Recommendations

• The American College of Rheumatology conditionally recommends hydroxychloroquine as first-line therapy for DMARD-naive patients with low disease activity, due to its favorable safety profile and better tolerability 1, 2
• For patients with moderate-to-high disease activity, methotrexate is strongly recommended over hydroxychloroquine due to superior disease-modifying properties and structural damage prevention 3

Disease Activity-Based Treatment Algorithm

• For low disease activity, hydroxychloroquine is the preferred first-line agent over sulfasalazine, methotrexate, and leflunomide, due to its superior tolerability and more favorable risk profile in RA patients 1, 2
• The European League Against Rheumatism (EULAR) guidelines characterize hydroxychloroquine as having weak disease-modifying effects with limited clinical efficacy and no structural efficacy 5

Role in Combination Therapy

• Hydroxychloroquine is used as part of triple therapy (methotrexate + sulfasalazine + hydroxychloroquine) to provide additive clinical benefit, with superior efficacy compared to monotherapy or dual therapy 6

Critical Pitfalls to Avoid

• The American College of Rheumatology recommends against using hydroxychloroquine as monotherapy for moderate-to-high disease activity RA, as it lacks sufficient disease-modifying properties and does not prevent structural damage 3, 5
• Clinical response requires 3-6 months of treatment for adequate assessment, and treatment failure should not be assessed before this time 6